Apollomics Inc. Warrant (NASDAQ:APLMW)
| Market Cap | 169.97M-26.8% |
| Revenue (ttm) | 8.50M+660.3% |
| Net Income | -10.94M+84.3% |
| EPS | 0.00-2089.3% |
| Shares Out | 14.78B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,226 |
| Open | 0.02 |
| Previous Close | 0.01 |
| Day's Range | 0.01 - 0.02 |
| 52-Week Range | 0.01 - 0.03 |
| Beta | 2.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 24, 2026 |
About APLMW
Apollomics, Inc. functions as a clinical-phase biotechnology enterprise, concentrating its efforts on discovering and advancing novel cancer treatments to meet crucial, underserved patient requirements. The company was co-founded by Liang Yu Guo and Sanjeev Redkar in 2015, with its main operations based in Foster City, California.
$APLMW stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in APLMW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by APLMW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
APLMW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New APLMW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to APLMW from public contracts
Source: USAspending.gov
APLMW Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from APLMW’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.